PDRN Explained

What PDRN Actually Is

PDRN — polydeoxyribonucleotide — is a DNA-fragment ingredient derived from salmon or trout sperm cells. It's not a synthetic peptide and it's not a growth factor in the strict definition. It's a mixture of DNA fragments, typically 50 to 1,500 kilodaltons in molecular weight, that triggers specific cellular responses when applied to or injected into skin.

The Korean dermatology industry popularized PDRN globally, but the underlying compound has been used medically in Europe since the 1950s — originally as a wound-healing adjunct in Italian hospitals. Mastelli S.r.l., an Italian pharmaceutical company, holds foundational patents on pharmaceutical-grade PDRN and sells it under the brand Placentex. Korean aesthetic use represents a newer application of an ingredient with a long medical history.

Two things get conflated in marketing copy that shouldn't be. PDN (polynucleotide) is structurally similar but has a different molecular weight distribution and is sometimes marketed as "next generation" PDRN. PN (polynucleotide long-chain) is another variant. For practical purposes, the clinical effects overlap significantly, but the specific PDRN evidence base is the largest.

How It Works

PDRN operates through three confirmed mechanisms. Understanding them matters because they explain which applications work and which don't.

1. Adenosine A2A receptor activation. PDRN fragments bind to adenosine A2A receptors on fibroblasts and other cells. This receptor activation drives upregulation of VEGF (vascular endothelial growth factor), which promotes new capillary formation in healing tissue. This is the mechanism behind PDRN's wound healing reputation and explains why it works particularly well on post-procedural skin.

2. Salvage pathway nucleotide supply. Cells synthesize new DNA through two pathways: de novo synthesis (energy-intensive, requires raw materials) and the salvage pathway (recycles existing nucleotides). PDRN fragments provide ready-made nucleotides to the salvage pathway, which is particularly valuable for cells under stress or undergoing rapid division. For skin, this means accelerated cell turnover and recovery in damaged tissue.

3. Anti-inflammatory signaling. A2A receptor activation also suppresses pro-inflammatory cytokines like TNF-alpha and IL-6. This is why PDRN-based products show measurable results on erythema, post-procedure inflammation, and barrier disruption — not just through regeneration but through active inflammation reduction.

What PDRN does not do: it does not cause DNA recombination or genetic modification. The fragments are too small and non-coding. Despite occasional marketing copy suggesting otherwise, PDRN does not "rewrite" skin DNA or "activate stem cells" in any meaningful sense. The mechanism is nucleotide supply and receptor signaling.

Salmon vs Trout Sources

Most PDRN on the Korean market is salmon-derived. A smaller portion is trout-derived. Practically, the difference is minimal for the end user:

• Salmon PDRN — the industry standard. Sourced from Pacific salmon (typically chum or sockeye) sperm cells. Mastelli's Placentex uses trout, but the Korean domestic industry standardized on salmon because of supply chain access to Alaskan and Russian salmon stocks.
• Trout PDRN — chemically nearly identical to salmon PDRN. Higher cost, marginal positioning advantage. Some premium European product lines specify trout.

Quality of extraction and processing matters more than the species. Poorly extracted PDRN contains protein and lipid contaminants that cause injection-site reactions and reduce topical efficacy. Pharmaceutical-grade PDRN goes through multiple purification steps including ultrafiltration, protease digestion, and HPLC verification. Cosmetic-grade PDRN in mass-market K-beauty products is typically lower purity.

Topical vs Injectable: What's Actually Different

This is the most commonly confused distinction in PDRN marketing, and understanding it correctly is essential for anyone evaluating products or discussing treatments with clinicians.

Injectable PDRN — the treatment Korean clinics call Rejuran (Pharma Research's brand), Juvelook PDLLA+PDRN combinations, and various generic PDRN skin boosters — is injected directly into the dermis. At this depth, PDRN fragments can directly reach fibroblasts, bind A2A receptors, and drive the full regenerative cascade. Injectable PDRN is a licensed medical device in Korea (의료기기 등급 2) and in most regulated markets outside Korea either requires physician administration under a similar medical-device classification or is not approved.

Topical PDRN — the cream, serum, and mask formats — applies PDRN to the stratum corneum and hopes it penetrates. Larger PDRN fragments (above 50 kDa) cannot meaningfully cross intact skin barrier. Smaller fragments can, especially when the barrier is compromised (post-procedure, damaged, or inflamed) or when delivery enhancers are included in the formulation.

This leads to a critical clinical insight: topical PDRN is most effective when the skin barrier is compromised. On intact healthy skin, topical PDRN delivers modest hydration and anti-inflammatory benefits. On post-procedure skin, laser-treated skin, or barrier-damaged skin, topical PDRN penetration increases significantly and benefits compound. This is why Korean clinics typically recommend topical PDRN products as post-procedure adjuncts rather than daily skincare replacements.

Will topical PDRN replicate injectable PDRN results? No. The delivery is different, the depth is different, and the concentration reaching active cells is orders of magnitude lower. A topical cream does not equal a skin booster series. This distinction gets deliberately blurred in consumer marketing; it should not be blurred in B2B contexts.

Clinical Use Cases

Based on Korean clinical practice and the published literature, PDRN has established evidence for several specific applications:

Post-procedure recovery. The strongest evidence base. After ablative laser (CO2, Er:YAG), fractional laser, microneedling, or chemical peel, PDRN — both topical and injectable — accelerates barrier restoration, reduces erythema duration, and shortens overall recovery time. Korean clinics routinely prescribe topical PDRN for the 7 to 14 days following significant procedures.

Chronic wound healing. The original medical application. Diabetic ulcers, pressure sores, burn recovery. Injectable PDRN is used in European hospitals for these indications. Not relevant to aesthetic practice but establishes the mechanistic evidence base.

Atrophic scar revision. Injectable PDRN, typically combined with microneedling or fractional laser, shows measurable improvement in acne scars over 3 to 6 month protocols. Topical PDRN alone has weaker evidence for scar revision.

Photoaging. Injectable PDRN skin booster series (4 to 6 sessions, 2 weeks apart) show dermal thickness increases on ultrasound and subjective improvement in fine lines and texture. Evidence for topical PDRN in photoaging is mixed and likely requires barrier compromise to be meaningful.

Hair loss. Scalp-injected PDRN, often combined with exosomes or PRP, shows early-stage evidence for androgenetic alopecia. Topical PDRN for hair is less established.

What the Research Shows

The PDRN evidence base is heavier in Korean and Italian medical literature than in English-language journals, which creates a skewed perception of the evidence weight.

A meaningful PubMed search on "polydeoxyribonucleotide" returns around 400 papers going back to the 1980s. Quality varies. The strongest studies are:

• Galeano et al. (2008) — demonstrated VEGF-mediated wound healing in diabetic mouse models. Foundational mechanism paper.
• Belletti et al. (2007) — A2A receptor binding and downstream signaling. Explains the anti-inflammatory effects.
• Lee et al. (2019, Korean Journal of Dermatology) — clinical trial on PDRN injection for atrophic acne scars, 8-week protocol.
• Kim et al. (2020) — comparison of PDRN injection vs microneedling for photoaging, 12-week results.

What's missing: large multi-center randomized controlled trials with long-term follow-up. The evidence base is solid enough for clinical confidence in established applications but thinner than, say, the evidence for botulinum toxin or HA fillers.

Concentration Matters: What to Look For

One of the most common sources of confusion in the Korean PDRN topical market is concentration disclosure. Many consumer K-beauty products list "PDRN" in the ingredient list without specifying concentration. This is largely marketing theatre — traces of PDRN have minimal effect.

Clinical-tier topical PDRN products typically specify concentration in one of two ways:

• ppm (parts per million) — the standard for serum and cream formulations. Effective topical PDRN products typically contain 500 to 2,000 ppm of active PDRN. Below 500 ppm is generally below the threshold for measurable effect.
• Percent — some brands use percentage notation. 0.05% to 0.2% is the comparable range.

When evaluating a topical PDRN product for B2B distribution, ask the supplier for concentration disclosure in writing. If the supplier cannot provide this information, the product is likely consumer-grade with trace PDRN included for marketing purposes rather than clinical effect.

Injectable PDRN products specify concentration differently, typically in mg/ml. Standard skin booster concentrations are 2 mg/ml to 20 mg/ml depending on product class.

Topical PDRN Product Landscape

Several Korean brands produce clinical-tier topical PDRN formulations. A representative (not exhaustive) overview:

Rejuran skincare line (Pharma Research) — the topical companion to the Rejuran Healer injectable. Includes Concentrate (serum), Moisturizer, Healing Cream, Healing Mask, and related formats. Positioned as post-procedure recovery skincare. Not a replacement for the injectable treatment.

Curenex topical line — cosmetic-side brand with PDRN-containing creams and masks. Often used in clinical post-procedure protocols.

Rejunera (DAESUNG MEDI) — unrelated to Rejuran despite the similar name. Combines PDRN with exosomes at specified clinical concentrations (2,000 ppm PDRN). Marketed for barrier repair.

Generic and private-label — many Korean contract manufacturers produce PDRN-containing creams that appear under various brand names. Concentration and purity vary widely.

The branding landscape is deliberately confusing. For B2B buyers, the practical path is to request supplier documentation (concentration, source, certificate of analysis) rather than relying on brand positioning.

Regulatory Status by Market

Korea: Topical PDRN products are cosmetics (화장품). Injectable PDRN is a medical device (의료기기 2등급). Both require Korean MFDS registration for domestic sale.

United States: Topical PDRN is legal as a cosmetic ingredient (subject to MoCRA registration as of 2024). Injectable PDRN is not FDA-approved. Importing injectable PDRN for medical use in the US is restricted and has been subject to import alerts.

European Union: Topical PDRN is legal as a cosmetic under Regulation 1223/2009. Injectable PDRN requires CE-marked medical device status; several brands have achieved this (Plinest is one example).

Southeast Asia: Varies significantly. Singapore, Thailand, and the Philippines generally allow topical PDRN cosmetics with proper ingredient notification. Injectable PDRN is typically handled as a medical device requiring country-specific registration.

Middle East: UAE allows topical PDRN cosmetics through standard cosmetic notification. Saudi SFDA requires specific cosmetic registration.

Questions Professionals Ask

"Can topical PDRN replace injectable treatments?" No. Different delivery, different depth, different clinical effect. Topical is a complement, particularly valuable post-procedure.

"What's the difference between PDRN 'Healer' and Polynucleotide 'HA' products?" Molecular weight distribution and formulation. Rejuran Healer is a skin-booster-class PDRN. Rejuran HB adds hyaluronic acid. Rejuran S is a lower-concentration variant. The naming conventions vary by manufacturer; there's no industry-wide standard.

"Is PDRN vegan-suitable?" No. All PDRN is derived from fish sperm cells. Vegan alternatives with similar marketing (plant-derived nucleotides) do not have comparable evidence.

"Does topical PDRN cause allergic reactions in people with fish allergies?" Theoretically possible but rare in clinical practice. PDRN is highly purified DNA without the proteins that typically cause fish allergy reactions. Patch testing is still recommended for known fish allergy patients.

"What's a realistic shelf life for topical PDRN products?" 24 to 36 months unopened, 3 to 6 months after opening. PDRN itself is stable; the formulation carriers (water, glycerin, preservatives) determine overall product shelf life.